Rapid Characterization of the SARS-CoV-2 Immune Response Using the Simple Western Multi-Antigen Serology Assay

The Simple Western automated western blotting platform accelerates characterization of the human IgG immune response to COVID-19.

The Scientist Creative Services Team
Oct 21, 2020

FREE Webinar

Tuesday, November 17, 2020
12:00 - 1:00 PM, Eastern Time

Register Now

The COVID-19 pandemic creates a need to better understand the SARS-CoV-2 immune response, including variability amongst individual human samples, temporal changes, and differences in vaccinated vs. natural immune responses. Using Simple Western automated hands-free western blotting platforms, scientists can rapidly perform SARS-CoV-2 antigen-down serology assays. The Simple Western SARS-CoV-2 Multi-Antigen Assay Module quantitatively characterizes serum or plasma human IgG antibodies reactive to five SARS-CoV-2 antigens within a 3-hour run and provides information-rich views into antibody binding profiles across individual human samples or over time. In this webinar brought to you by ProteinSimple, scientists at RAIN Incubator will present insights acquired using the Simple Western SARS-CoV-2 Multi-Antigen Assay to quickly compare human immune responses to five key viral antigens across a wide range of sample types, temporal serum draws, and dilutions.

Topics to be covered

  • Data-rich profiles of human serum IgG antibodies reactive to multiple recombinant SARS-CoV-2 antigens
  • Characterization of the Simple Western SARS-CoV-2 multi-antigen assay including sensitivity & comparison to an in-house SARS-CoV-2 IgG ELISA assay
  • Observed variability in COVID-19 human immune responses and immune response evolution over time
  • Specific immune fingerprints that may be indicative of disease progression, immunity status or other clinical outcomes

Register Now


Paul Johnson
Product Manager
Strategy and New Product Development
ProteinSimple, a Bio-Techne brand

Featured Speaker

Shah A. K. Mohamed Bakhash
Research Assistant
RAIN Incubator


November 2020

Death on the shore

Researchers investigate recent gray whale strandings along North America’s Pacific coast


Sponsored Product Updates

Twist Bioscience and Biotia Announce Research Use Only Availability of First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay for Characterization and Surveillance of the Virus
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today announced the availability of an important new research tool for the sequencing and surveillance of COVID-19.
The Rise of Cannabis Extraction Labs
Scientists in cannabis extraction laboratories are bravely pioneering a new field of agro-chemical engineering.
Expanding Cell Growth Capabilities
Download this eBook to learn how to optimize large-scale cell growth using culture shakers, incubators, and bioreactors!
SynDevRx Announces Positive Data from Phase 1 Safety Trial of SDX-7320 in Late Stage Cancer Patients
SynDevRx has submitted to the FDA results from a Phase 1 dose escalation study in patients with metastatic and progressing solid tumors to assess the safety and tolerability of SDX-7320. Additional outcome measures suggest that SDX-7320 may slow the rate of disease progression and formation of new metastases. Exploratory endpoints suggest that SDX-7320 may induce favorable changes to insulin and insulin resistance and other key metabolic hormones (leptin, adiponectin) as well as to multiple angiogenic biomarkers.